Am­gen read­ies PhI­II tri­al for first Op­di­vo biosim­i­lar, with launch un­like­ly be­fore 2028

The race to end Bris­tol My­ers Squibb’s ex­clu­siv­i­ty on its megablock­buster can­cer drug Op­di­vo (nivolum­ab) is be­gin­ning in earnest, with Am­gen look­ing to kick off a Phase III tri­al next month for its po­ten­tial biosim­i­lar to the drug.

The ran­dom­ized, dou­ble-blind tri­al aims to en­roll 620 par­tic­i­pants and eval­u­ate the ef­fi­ca­cy, safe­ty, and im­muno­genic­i­ty of the biosim­i­lar, known as ABP 206, when com­pared with Op­di­vo in sub­jects with treat­ment-naïve un­re­sectable or metasta­t­ic melanoma, ac­cord­ing to a new list­ing on a gov­ern­ment data­base of tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER